Amaze Holdings to Join Adobe Conference This Fall
Amaze Holdings, Inc. (NYSE: AMZE) shares retreated, as the global leader in creator-powered commerce announced it will participate in Adobe MAX - The Creativity Conference, taking place October 28-30 in Los Angeles. As part of its presence, Amaze will host a first-of-its-kind creator confessional experience featuring an interactive booth where creators can candidly share their thoughts and challenges within the creator economy. This bold, creator-first initiative is designed to surface honest creator insights that are often left unspoken in the industry.The collected responses will directly inform a speaking session by Amaze CEO Aaron Day, who will address those sentiments, offering practical solutions to pressing challenges and issuing a call to collective action for creators and businesses operating in the creator economy.“Adobe MAX is the pinnacle event for creators across the industry,” said Day. “As a company committed to empowering creators, this is a vital opportunity to not only share our story but to listen. We are seeking to bring creators’ voices to the forefront during our session and explore how we can address their biggest challenges together.”Amaze Software, Inc. is an end-to-end, creator-powered commerce platform offering tools for seamless product creation, advanced e-commerce solutions, and scalable managed services.AMZE shares sank 43 cents, or 5.8%, to $6.94 Monday.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


